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Abstract
Background: The 2010 Infectious Diseases Society of America (IDSA) guidelines for management of cryptococcal
diseases recommend high dose fluconazole (≥ 800 mg/day), either alone or with other antifungal drugs, as
alternative anticryptococcal choices. But evidence for its use in the treatment of HIV-uninfected cryptococcal
meningitis (CM) remains sparse.
Methods: A retrospective analysis of HIV-uninfected CM patients who received fluconazole 800 mg/day for salvage
therapy from January 2011 to December 2016 at Huashan Hospital, Shanghai, China was performed. Efficacy and
safety were assessed, and mortality and prognostic factors evaluated.
Results: A total of 44 patients were studied including 19 refractory to amphotericin B induction therapy, 8
refractory to fluconazole consolidation therapy (400 mg/d), and 17 intolerant of antifungal drugs. For salvage, 11
patients received triple therapy of high dose fluconazole, amphotericin B and flucytosine, 20 received dual therapy
of high dose fluconazole and flucytosine, 13 received monotherapy of high dose fluconazole. Median duration of
high dose fluconazole in salvage regimens was 136.5 days (range, 1–667 days). Clinical response rates were 72.1%
(31/43) and 83.7% (36/43) when assessed at 2 weeks and the end of salvage therapy, respectively. Adverse events
possibly related to high dose fluconazole occurred in 54.5% (24/44) of the patients, and all were mild or moderate.
From the initiation of salvage therapy, 1-year all-cause mortality was 13.6% (6 of 44 patients) among the study
population with no significant difference in refractory or intolerant patients.
Conclusions: Adherence to guideline recommendations of high dose fluconazole, alone or in combination with
other antifungals, was safe and often effective for salvage therapy of HIV-uninfected CM patients.
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Background
Cryptococcal meningitis (CM) is the most common
opportunistic fungal infection of the central nervous
system (CNS). The vast majority of cases are caused by
Cryptococcus neoformans, while Cryptococcus gattii is
more geographically restricted [1]. According to an up-
dated estimate, over 220,000 cases of CM occur each
year in HIV-infected patients, resulting in 181,000
deaths in 2014 [2]. Owing to the advent of highly active
antiretroviral therapies, the incidence of HIV-infected
CM has decreased and the long-term survival rate has
increased in developed countries in recent years [3].
However, a growing number of CM cases occur in
HIV-uninfected hosts with solid organ transplants, innate
immunodeficiency and immune disorders, exogenous
immunosuppressant administration, and even apparently
normal immune status [4]. Mortality rate in these patients
was as high as 25–40%, which was no lower than that in
HIV-infected CM patients [5–8]. As a very heterogeneous
group, HIV-uninfected CM patients pose great thera-
peutic challenges to clinicians.
Fluconazole is a triazole with excellent in vitro and in
vivo activity against Cryptococcus. It has been widely
used in CM as consolidation and maintenance therapy,
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usually at a dosage equal to or lower than 400 mg/day.
In resource-limited areas, fluconazole alone has been
used for induction therapy, and proved to be a poorly ef-
fective drug with 10-week mortality consistently > 50%
even at high dosage [9–12]. But the efficacy was accept-
able or favorable when high dose fluconazole was used
in combination with other antifungal drugs or as en-
hanced consolidation therapy [13–18]. In the 2010 Infec-
tious Diseases Society of America (IDSA) guidelines,
higher dose fluconazole alone or in combination with
other antifungals was recommended for both consolida-
tion and salvage therapy in HIV-uninfected CM patients,
compared with 400 mg/day in the 2000 version of these
guidelines [19, 20]. However, evidence of high dose
fluconazole for treatment of CM was mainly based on
studies of HIV-infected populations, and remained
sparse in HIV-uninfected patients. Therefore, we con-
ducted a retrospective study among HIV-uninfected CM
patients who received fluconazole 800 mg/day for sal-
vage therapy, and evaluated the efficacy and safety of
high dose fluconazole regimens.
Methods
Study design
This is a retrospective cohort study conducted among
HIV-uninfected CM patients from January 2011 to De-
cember 2016 at Huashan Hospital, Fudan University (a
tertiary health care center in Shanghai, China, with ap-
proximately 1200 hospital beds and 60,000 admissions
per year). Patients who had been refractory to or intoler-
ant of prior antifungal drugs and who then switched to
salvage therapy with fluconazole 800 mg/day were in-
cluded. This study was reviewed and approved by the
local medical ethics committee.
Definitions
A proven diagnosis of CM was made if the patient met
any of the following criteria: (1) positive culture of Cryp-
tococcus from cerebrospinal fluid (CSF), (2) positive CSF
ink smear, (3) cryptococcal capsular polysaccharide anti-
gen detected in CSF on cryptococcal antigen (CrAg) lat-
eral flow assay (IMMY, Inc., Norman, Oklahoma, USA)
in CSF or (4) compatible histopathological findings,
which are 5–10 μm encapsulated yeasts in brain tissue.
Refractory CM was considered if any 2 of the following
conditions were present after an adequate period of anti-
fungal therapy (≥14 days): (1) persistently positive cul-
tures of Cryptococcus in CSF, (2) deterioration of clinical
signs and symptoms of disease, (3) new sites of disease
or worsening of pre-existing lesions radiologically, and
(4) decreasing level of glucose and increasing level of
protein in CSF [21, 22]. Patients were considered as in-
tolerance to antifungal drugs if they suffered severe or
life-threatening toxicity from amphotericin B (AmB)
based initial therapy [22].
Efficacy and safety assessment
Patients treated with high dose fluconazole for ≥1 week
were included for efficacy evaluation. Response to
salvage therapy was assessed at 2 weeks after initiation
of salvage therapy, at the end of salvage therapy, and at
the end of antifungal therapy. Efficacy of antifungal
treatment was categorized as success (complete or
partial response) or failure (stable response, disease
progression, or death during the study period regardless
of any cause) on the basis of clinical, radiological, and
microbiological data according to previous criteria [21].
Adverse events (AEs) occurring during salvage therapy
were recorded. The relationships of AEs and high dose
fluconazole were evaluated with Naranjo probability
scale [23]. High dose fluconazole related AEs were
defined as one with a possible, probable or certain
relationship.
Statistical analysis
Continuous variables were compared with t test or the
non-parametric Mann-Whitney test. Proportions were
compared with the χ2 test or Fisher’s exact test, as
appropriate. Log-rank test was used in univariate ana-
lysis for prognostic factors of 1-year survival, and Cox
proportional hazards model for identification of inde-




In total, 44 patients with proven CM were included in
our study. Thirty-two also had pulmonary involvement
and 6 cryptococcemia. The median age was 44 years,
and 63.6% were male. Predisposing factors co-existed in
16 patients (36%). Detailed information is summarized
in Table 1. Headache (100%) was the most common
symptom, and 72.7% of them presented with fever,
vomiting and meningeal irritation. Thirty-four patients
presented with further neurological symptoms and signs,
including altered mental status, epileptic seizures, cranial
nerve deficits, limb weakness, uracratia and dysuria
(Table 1).
Image findings
Cranial magnetic resonance imaging (MRI) was per-
formed in all patients, with 41/44 (93.2%) yielding
abnormal results. Local parenchymal lesions (86.4%)
were most frequently observed, and common sites in-
cluded frontal lobe (68.2%), parietal lobe (59.1%), peri-
ventricular region (29.5%) and basal ganglion (22.7%).
Other abnormalities included meningeal enhancement
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(25 patients; 56.8%) and ventricular enlargement (12
patients; 27.3%). Most patients had 2 or more sites of
involvement. Abnormalities on chest computer tomog-
raphy (CT) scans were found in 32 of 44 patients (72.3%).
The common findings were nodules and masses (47.7%),
patches and strips (43.9%), pleural thickening (22.7%),
pleural effusion (20.5%), lymph node enlargement
(6.8%), air bronchogram sign (4.5%) and ground glass
attenuation (2.3%). Some patients had mixed types of
lesion on chest CT.
CSF findings
Before initiating salvage therapy, CSF examinations were
performed in 43 patients including 42 samples from
lumbar punctures, 1 from continuous lumbar cerebro-
spinal fluid drainage. CSF cultures were positive for
Cryptococcus in 4 patients, and ink smears were positive
in 18 patients. CSF CrAg tests were positive in all 43
patients, and 47.7% of them (21/43) had CrAg titer of at
least 1:640. Median white blood cell count (WBC) of
CSF was 29 /mm3 (range, 0–550 /mm3). Median levels
of CSF protein and glucose were 824 mg/dL and
34 mg/dL, respectively. Of the 42 patients who had
lumbar punctures, 21 had CSF opening pressure above
25 cm H2O.
Antifungal therapy
As listed in Fig. 1, 19 patients (43.2%) were refractory to
initial antifungal therapy, 8 (18.2%) were refractory to
consolidation therapy, and 17 (38.6%) were intolerant of
prior antifungals. AmB-based regimens were initially
administered in all 44 patients, and daily dosage of AmB
ranged from 20 to 40 mg (0.4–0.7 mg/kg/day). Median
cumulative dose and duration of AmB were 1205 mg
(range, 205–5775 mg) and 48.5 days (range, 9–212 days).
Of the 19 patients refractory to initial therapy, 11 re-
ceived high dose fluconazole in combination with AmB
and flucytosine for salvage, 6 received high dose flucona-
zole and flucytosine, and the remaining 2 received high
dose fluconazole alone. For patients who were refractory
to consolidation therapy, fluconazole dosage was in-
creased from 400 mg/day to 800 mg/day and flucytosine
co-administered in all but one patient. Of the 17
antifungal-intolerant patients, 10 received high dose flu-
conazole alone, and 7 others were treated with high dose
fluconazole and flucytosine. Overall, triple therapy of
high dose fluconazole, AmB and flucytosine was admin-
istered in 11 patients, 20 received dual therapy of high
dose fluconazole and flucytosine, 13 received monother-
apy of high dose fluconazole. Median duration of high
dose fluconazole in salvage therapy for the 44 patients
was 136.5 days (range, 1–667 days). Among the 31 pa-
tients (70.5%) receiving flucytosine, 27 were treated with
flucytosine throughout the course, and the remaining 4
discontinued the drug for suspected side effects (3 with
anemia, 1 with elevated transaminase). Median duration
of flucytosine in salvage therapy for the 31 patients was
142 days (range, 22–561 days).
Efficacy and outcome
Except 1 patient who received high dose fluconazole less
than 7 days and died of multiple organ failure (MOF), the
other 43 patients were all included into efficacy evaluation.
Two weeks after salvage therapy, partial response in 31
patients (72.1%), stable response in 11 patients (25.6%),
Table 1 Baseline characteristics, signs and symptoms of 44
cryptococcal meningitis patients treated with high dose
fluconazole for salvage therapy
Variables No. (%) of patients
Sex, male 28 (63.6)
Age, years 44 (range, 16–73)
Predisposing factors




Solid tumora 2 (4.5)
SLE 5 (11.4)
Cirrhosis 2 (4.5)
Liver transplantation 1 (2.3)
Splenectomy 1 (2.3)
Type 2 diabetes mellitus 2 (4.5)




Meningeal irritation 32 (72.7)
Seizure 16 (36.4)
Altered mental statusb 12 (27.3)
Cranial nerve defect
Impaired vision 16 (36.4)
Diplopia 8 (18.2)
Visual field defect 8 (18.2)
Ophthalmodynia 3 (6.8)
Hearing impairment 18 (40.9)
Facial paralysis 3 (6.8)
Limb weakness 14 (31.8)
uracratia 3 (6.8)
Dysuria 3 (6.8)
MDS myelodysplastic syndrome; SLE systemic lupus erythematosus; ITP
idiopathic thrombocytopenia
aIncluding 1 gastric cancer and 1 cholangiocellular carcinoma
bPatients with scores less than 15 by Glasgow Coma Scale
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and death caused by brain hernia in 1 patient (2.3%) were
observed. At the end of salvage therapy, 3 patients (7.0%)
achieved complete response, 33 (76.7%) achieved partial
response, 2 (4.7%) achieved stable response, and 5 (11.6%)
died. The overall efficacy rate was 83.7%. Of the 2 stable
patients, 1 discontinued fluconazole, reinstituted with
AmB and flucytosine and achieved partial response; the
other was lost for follow-up 40 days after initiation of sal-
vage therapy. Of the 4 patients who died after 2 weeks of
salvage therapy, 1 was considered to have died of CM, 2
died from secondary infection and MOF, and 1 died from
aggravation of lymphoma. Thirty-seven of 43 patients
(86.0%) achieved clinical success and stopped antifungal
drugs, 5 (11.6%) died and 1 (2.3%) was lost for follow-up.
As shown in Table 2, we compared the response rates be-
tween patients treated with high dose fluconazole with or
without flucytosie and those with combinations of AmB
and high dose fluconazole with or without flucytosine.
Fig. 1 Profiles of initial therapy and salvage therapy in 44 difficult-to-treat cryptococcal meningitis patients. AmB amphotericin B; 5FC flucytosine; Vor
voriconazole; L-Flu low dose fluconazole (≤ 400 mg/day); H-Flu high dose fluconazole (800 mg/day); CR complete response; PR partial response; DILI
drug induced liver injury. Addition or removal of 5FC during initial and salvage therapy were not listed. An example for reading the figure: * means
that the patient received AmB and flucytosine for a duration of 23 days as induction therapy, followed by consolidation therapy with low dose
fluconazole for 142 days, and then switched to salvage therapy with high dose fluconazole for 246 days, and finally achieved partial response at the
end of salvage therapy





H-Flu + AmB ± 5FC
(N = 11)
P-value
2-week of Salvage Therapy 31 (72.1) 20 (62.5) 11 (100) 0.019
End of Salvage Therapy 36 (83.7) 27 (84.4) 9 (81.8) > 0.999
End of Antifungal Therapy 37 (86.0) 27 (84.4) 10 (90.9) > 0.999
H-Flu high dose fluconazole (800 mg/day); AmB Amphotericin B; 5FC flucytosine
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Although a significant higher 2-week response rate was
observed in the triple combination group (62.5% vs. 100%,
P = 0.019), there was no apparent differences in efficacy at
the end of salvage therapy (84.4% vs. 81.8%, P > 0.999)
and the end of antifungal therapy (84.4% vs. 90.9%,
P > 0.999). At 1-year follow-up after stopping antifungal
drugs, all of the 37 successfully treated patients survived,
and no relapses were observed.
Safety
All 44 patients were included in the safety assessment.
Possible high-dose fluconazole related AEs were found
in 54.5% (24/44) of them. No grade 3 or 4 AEs were ob-
served. As shown in Table 3, the most frequent AE was
elevated transaminase level in 11 patients. Transient
grade 2 neutropenia and grade 1 thrombocytopenia oc-
curred in 1 patient treated with fluconazole monotherapy.
One patient presented with grade 2 anemia in the first
week of salvage therapy, but his hemoglobin level recov-
ered without discontinuance of fluconazole or flucytosine.
Hypokalemia occurred in 3 patients, all of whom returned
to normal condition after potassium supplementation
(AmB were not co-administrated). There were no in-
creased creatinine levels related to high dose fluconazole
in our cases.
In terms of clinical manifestations, gastrointestinal side
effects were common complaints. Skin lesions were docu-
mented in 2 patients. Photosensitive dermatitis occurred
in 1 patient soon after initiation of fluconazole, and im-
proved without fluconazole discontinuance. Rash devel-
oped in another patient several weeks after the salvage
therapy and lasted until CM recovered and antifungal
treatment finished. We also observed 1 patient with
elevated D-dimer and deep venous thrombosis which was
relieved after treatment with oral warfarin. None of these
patients discontinued high dose fluconazole due to
intolerance.
Mortality and prognostic factors
From the beginning of salvage therapy, 1-year mortality
related to all cause was 13.6% (6 of 44 patients) with no
significant difference among 3 treatment groups (Fig. 2,
P = 0.258). We assessed factors with a potential impact
on all-cause mortality by means of univariate and multi-
variate analyses. In the univariate model, factors signifi-
cantly associated with 1-year mortality were age ≥ 60 years
(P = 0.001); serum albumin level < 35 g/L (P = 0.001); esti-
mated glomerular filtration rate (eGFR) < 60 mL/min/
1.73m2 (P = 0.015); and CSF WBC count < 10 /mm3
(P = 0.002). CSF CrAg titer ≥1280 was more frequently
presented in mortality group but it did not reach a statistic
significance (P = 0.058). By multivariate analysis, as shown
in Table 4, factors significantly correlated with decreased
survival in the overall population were serum albumin
level < 35 g/L (P = 0.014) and CSF CrAg titer ≥1280
(P = 0.048).
Discussion
In 1996, Pappas et al. reported 12 HIV-uninfected CM pa-
tients who received high dose fluconazole, 800 mg/day, in
Table 3 High dose fluconazole related adverse events in 44
cryptococcal meningitis patients











Nausea and vomitting 5 (11.4)
Constipation 3 (6.8)
Dry mouth 2 (4.5)
Dry eyes 1 (2.3)
Skin lesion 2 (4.5)
Numbness of upper limb 1 (2.3)
Thrombosis of lower limb 1 (2.3)
GGT gama-glutamyltransferase; ALT alanine aminotransferase; AST aspartate
aminotransferase; ALP alkaline phosphatase
aAll laboratory abnormalities were grade 1 or grade 2 only
Fig. 2 All-cause mortality in three groups of cryptococcal meningitis
patients treated with high dose fluconazole for salvage therapy. Unk
status unknown
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their induction therapy or as consolidation therapy [24].
However, since then, no published study has specifically
addressed the use of high dose fluconazole in the manage-
ment of HIV-uninfected cryptococcal infections. The re-
sults of our study showed that high dose fluconazole
(800 mg/day) either alone or in combination with other
antifungal drugs had favorable effects and was well toler-
ated among HIV-uninfected CM patients.
AmB-based regimens are recommended to optimize
fungal clearance and survival for both HIV-infected and
HIV-uninfected CM patients [19]. Despite given appropri-
ate treatment, 25–35% patients experience refractory
cryptococcal infections or drug intolerance [5, 6, 18, 25,
26]. In previous trials with AmB lipid complex, posacona-
zole and voriconazole used as salvage therapies, the overall
efficacy rates were not impressive, with success rates no
more than 50% [22, 27, 28]. Recombinant IFN-γ treatment
as salvage therapy was tested only in case reports, and this
form of adjunct could be detrimental in non-HIV infec-
tions, depending on host immune responses [29–31]. In
our study, after salvage therapy with fluconazole 800 mg/
day for a median of 137 days, 72% achieved effective re-
sponse in 2 weeks, and 84% achieved effective response at
the end of salvage therapy. Consistent with our findings,
the good efficacy of high dose fluconazole as salvage ther-
apy was also reported in HIV-infected CM patients, with
6 out of 8 patients (75%) achieving microbiological im-
provement after a mean course of 4.5 months, showed as
either sterile CSF culture or decreased CSF CrAg titers
[32]. Compared with patients treated with high dose flu-
conazole with or without flucytosine, there was signifi-
cantly improved efficacy at 2 weeks in patients treated
with AmB and high dose fluconazole with or without flu-
cytosine. However, no apparent differences were showed
in the long term outcomes between the two groups at the
end of salvage therapy and the end of antifungal therapy.
In our study, no significant difference in 1-year mor-
tality rates was found among patients with refractory in-
fections and those intolerant of prior antifungal drugs.
Factors linked with poor prognosis in our patients were
older age, renal dysfunction, lower CSF white cell count,
and high CSF CrAg titers, as consistent with previous
reports in HIV-uninfected population [5, 6, 25, 33].
Though previous reports found altered mental status to
be an additional factor, it was more common in patients
died of active disease and not significant in our present
study. Compared with an overall mortality rate of 25–
40% reported in the previous studies of HIV-uninfected
CM population [5–7], a relatively lower mortality rate of
13.6% after 1 year of salvage therapy was observed in
our study.
In previous studies of treatment for cryptococcal or
other fungal infections, fluconazole was well tolerated at
dosages from 800 to 2000 mg/day [9–13, 34–37]. Con-
sistent with previous studies, nausea and vomiting were
common in patients treated with fluconazole, especially
early in the course of treatment. Liver enzyme abnor-
malities were usually asymptomatic and self-limiting. In
our study, 10 of the 17 antifungal-intolerant patients had
AmB-related renal insufficiency and switched to salvage
regimens. Of note, further deterioration of renal func-
tion related to high dose fluconazole was not observed,
suggesting that high dose fluconazole with or without
flucytosine were well tolerated for patients with AmB in-
duced renal impairment.
There were some limitations to this work. As we in-
cluded a limited number of cases in the present study
and did not include a group of patients who received
low dose fluconazole as a control, the results should be
interpreted with caution. Only a few patients were cul-
ture positive when changed to salvage therapy. For these
patients, the reasons for “failure” may be due to the poor
Table 4 Univariate and multivariate analysis of factors associated with 1-year mortality among 44 cryptococcal meningitis patients
Factor Univariate Analysis Multivariate Analysis
Total No. of patients No. (%) of patients who died P-valueb P-value RR (95% CI)
Age≥ 60 years 12 4 (33.3) 0.022
Initial AmB course < 6 weeks 10 3 (30.0) 0.095
Salvage therapy without 5FC 13 3 (23.1) 0.196
Serum albumin level < 35 g/L 13 5 (38.5) 0.001 0.014 16.23 (1.78–148.19)
eGFR < 60 mL/min/1.73m2 8 3 (37.5) 0.015
CSF WBC count < 10 /mm3a 14 4 (28.6) 0.012
CSF glucose level < 36 mg/dLa 22 1 (4.5) 0.127
CSF CrAg titer ≥ 1280a 17 4 (23.5) 0.058 0.048 9.30 (1.02–84.73)
AmB Amphotericin B; 5FC flucytosine; eGFR estimated glomerular filtration rate; CrAg cryptococcal capsular antigen; CSF cerebrospinal fluid; WBC white blood cell
aData of CSF WBC count, CSF glucose level and CSF cryptococcal antigen titter was unavailable in 1 dead patient
bFactor entered the initial univariate analysis included male, age ≥ 60 years, time before diagnosis ≥60 days, predisposing factors, pulmonary involvement, seizure,
altered mental status, parenchyma lesions of brain MRI, initial AmB course < 6 weeks, salvage therapy without 5FC, serum albumin level < 35 g/L, eGFR < 60 mL/
min/1.73m2, CSF WBC count < 10 /mm3, CSF protein level > 500 mg/dL, CSF glucose level < 36 mg/dL, CSF CrAg titer ≥1280. Only predictors with a P-value less
than 0.2 were listed in the table
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efficacy of previous therapy, dysfunctional immune re-
sponses, or associated underlying conditions, and some
may have done well if the previous antifungal therapy
had been continued. Hence, multicenter randomized
controlled trials are needed for making a further object-
ive evaluation.
Conclusions
Evidence for the use of high dose fluconazole in
HIV-uninfected CM patients remains sparse. Our study
specifically addressed the efficacy and safety of high dose
fluconazole in this population and suggested that flucon-
azole 800 mg/day alone, or in combination with other
antifungal drugs was a safe and promising choice for
HIV-uninfected CM patients. Either refractory cases or
those intolerant to prior antifungal drugs can achieve fa-
vorable outcomes after receiving high dose fluconazole
as salvage therapy.
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